HIGHLIGHTS
- who: Francesco Morra from the Institute for the Experimental Endocrinology and Oncology, Research National Council, CNR, Naples, Italy have published the research: CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer, in the Journal: (JOURNAL)
- what: The authors scored and in primary UBC and the authors evaluated the of in correlation with the effects of the PARP-inhibitors combined with the P5091 in vitro. In this investigation the aim has been to analyse CCDC6 and USP7 expression levels in a series of primary urothelial bladder cancer, arranged in a . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.